Current Report Filing (8-k)
January 08 2021 - 07:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): January 8, 2021
Aquestive Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
Delaware
|
001-38599
|
82-3827296
|
(State or Other Jurisdiction of Incorporation or
Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
30
Technology Drive
Warren, NJ 07059
(908)
941-1900
(Address, Including Zip Code, and Telephone Number, Including Area
Code, of Registrant’s Principal Executive Offices)
Not
Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
☐ |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to
Section 12(b) of the Act:
Title of each
class
|
Trading
Symbol(s)
|
Name of each
exchange on which registered
|
Common Stock,
par value $0.001 per share
|
AQST
|
Nasdaq Global
Market
|
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 |
Regulation FD Disclosure.
|
Aquestive Therapeutics, Inc. (the “Company”)
is furnishing this Current Report on Form 8-K in connection with
the disclosure of information, in the form of an investor
presentation, to be given at meetings with institutional investors,
analysts and others. This information may be amended or
updated at any time and from time to time through another Current
Report on Form 8-K, a later company filing or other means. A
copy of the Company’s investor presentation is attached hereto as
Exhibit 99.1 to this Current Report on Form 8-K and incorporated
into this Item 7.01 by reference and replaces in its entirety all
prior investor presentations filed by the Company. The
investor presentation is available on the Company’s website located
at www.aquestive.com, although the Company reserves the right to
discontinue that availability at any time.
The
information in this Item 7.01 (including Exhibit 99.1) shall not be
deemed to be “filed” for purposes of, or otherwise subject to the
liabilities of, Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in any such filing.
Item 9.01 |
Financial
Statements and Exhibits
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
Investor
presentation.
|
Pursuant to
the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Dated: January 8, 2021
|
Aquestive Therapeutics,
Inc.
|
|
|
|
|
By:
|
/s/ A. Ernest Toth, Jr.
|
|
|
Name: A. Ernest Toth, Jr.
|
|
|
Title: Interim Chief Financial
Officer
|